Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: the CRESCEND study

被引:38
|
作者
Kim, Jae-Min [1 ]
Kim, Sung-Wan [1 ]
Stewart, Robert [2 ]
Kim, Seon-Young [1 ]
Yoon, Jin-Sang [1 ]
Jung, Sung-Won [3 ]
Lee, Min-Soo [4 ]
Yim, Hyeon-Woo [5 ]
Jun, Tae-Youn [6 ]
机构
[1] Chonnam Natl Univ, Sch Med, Dept Psychiat, Kwangju 501757, South Korea
[2] Inst Psychiat, Epidemiol Sect, London, England
[3] Keimyung Univ, Sch Med, Dept Psychiat, Taegu, South Korea
[4] Korea Univ, Coll Med, Dept Psychiat, Seoul 136705, South Korea
[5] Catholic Univ Korea, Coll Med, Dept Prevent Med, Seoul, South Korea
[6] Catholic Univ Korea, Coll Med, Dept Psychiat, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
depression; remission; anxiety; parasuicide; Korea; STAR-ASTERISK-D; MAJOR DEPRESSION; OUTPATIENTS; SERTRALINE; ANXIETY; COMORBIDITY; VENLAFAXINE; CITALOPRAM; RECOVERY; SYMPTOMS;
D O I
10.1002/hup.1168
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To estimate the 12-week remission rate of patients with depressive disorders and predictors of this in a naturalistic clinical setting in South Korea. Methods For people with DSM-IV depressive disorders about to receive treatment at 18 hospitals, data on sociodemographic and health status were obtained. A free choice of clinical interventions was allowed and naturalistic follow-up took place at 1, 2, 4, 8, and 12 weeks later. Remission was defined as a Hamilton Depression Rating Scale score of <= 7 sustained to 12 weeks or last follow-up, if earlier. Results For 723 participants, the 12-week remission rate was 31.4%. Remission was more likely in women, and in patients without a prior history of suicide attempt, and those with lower baseline anxiety. Conclusions Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and previous suicide attempt were markers of worse outcome. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:41 / 50
页数:10
相关论文
共 50 条
  • [1] Physical comorbidity and 12-week treatment outcomes in Korean patients with depressive disorders: The CRESCEND study
    Kim, Jae-Min
    Stewart, Robert
    Bae, Kyung-Yeol
    Yang, Su-Jin
    Yoon, Jin-Sang
    Jung, Sung-Won
    Lee, Min-Soo
    Yim, Hyeon-Woo
    Jun, Tae-Youn
    [J]. JOURNAL OF PSYCHOSOMATIC RESEARCH, 2011, 71 (05) : 311 - 318
  • [2] Predictors of remission in a national sample of patients with depressive disorders: the CRESCEND study
    Kim, J. M.
    Yoo, J. A.
    Yang, S. J.
    Kim, S. W.
    Shin, I. S.
    Yoon, J. S.
    Kim, J. B.
    Lee, M. S.
    Lim, H. W.
    Jun, T. Y.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S336 - S337
  • [3] Prediction of 12-Week Remission by Psychopharmacological Treatment Step in Patients With Depressive Disorders
    Jin, Yun-Tae
    Kim, Ha-Yeon
    Jhon, Min
    Kim, Ju-Wan
    Kang, Hee-Ju
    Lee, Ju-Yeon
    Kim, Sung-Wan
    Shin, Il-Seon
    Kim, Jae-Min
    [J]. PSYCHIATRY INVESTIGATION, 2022, 19 (10) : 866 - +
  • [4] Associations of Serum Serotonin Levels with 12-week and 12-month Remission in Patients with Depressive Disorders
    Choi, Wonsuk
    Kang, Hee-Ju
    Kim, Ju-Wan
    Kim, Hee Kyung
    Kang, Ho-Cheol
    Lee, Ju-Yeon
    Kim, Sung-Wan
    Stewart, Robert
    Kim, Jae-Min
    [J]. CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2022, 20 (02) : 248 - 258
  • [5] Gender differences in 12-week antidepressant treatment outcomes for a naturalistic secondary care cohort: The CRESCEND study
    Yang, Su-Jin
    Kim, Sun-Young
    Stewart, Robert
    Kim, Jae-Min
    Shin, Il-Seon
    Jung, Sung-Won
    Lee, Min-Soo
    Jeong, Seung-Hee
    Jun, Tae-Youn
    [J]. PSYCHIATRY RESEARCH, 2011, 189 (01) : 82 - 90
  • [6] Prospective associations of multimodal serum biomarkers with 12-week and 12-month remission in patients with depressive disorders receiving stepwise psychopharmacotherapy
    Kim, Jae-Min
    Kang, Hee-Ju
    Kim, Ju-Wan
    Jhon, Min
    Choi, Wonsuk
    Lee, Ju-Yeon
    Kim, Sung-Wan
    Shin, Il-Seon
    Kim, Min-Gon
    Stewart, Robert
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2022, 104 : 65 - 73
  • [7] Gender differences in 12 week treatment outcomes in Korean depressive patients: a report of CRESCEND study
    Yang, S.
    Yoo, J.
    Bae, K.
    Kim, J.
    Shin, I.
    Kim, S.
    Yoon, J.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S337 - S338
  • [8] Prevalence and Clinical Correlates of Insomnia in Depressive Disorders: The CRESCEND Study
    Park, Seon-Cheol
    Kim, Jae-Min
    Jun, Tae-Youn
    Lee, Min-Soo
    Kim, Jung-Bum
    Jeong, Seung-Hee
    Park, Yong Chon
    [J]. PSYCHIATRY INVESTIGATION, 2013, 10 (04) : 373 - 381
  • [9] CrossFit and the Epidemiology of Musculoskeletal Injuries: A Prospective 12-Week Cohort Study
    de Queiroz Szeles, Paulo Roberto
    da Costa, Taline Santos
    da Cunha, Ronaldo Alves
    Hespanhol, Luiz
    Pochini, Alberto de Castro
    Ramos, Leonardo Addeo
    Cohen, Moises
    [J]. ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE, 2020, 8 (03)
  • [10] A prospective 12-week study of quetiapine in adolescents with schizophrenia spectrum disorders
    Schimmelmann, Benno Graf
    Mehler-Wex, Claudia
    Lambert, Martin
    Schulze-zur-Wiesch, Constanze
    Koch, Eginhard
    Flechtner, Hans Henning
    Gierow, Baerbel
    Maier, Joachim
    Meyer, Eberhard
    Schulte-Markwort, Michael
    [J]. JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2007, 17 (06) : 768 - 778